Search results
Results From The WOW.Com Content Network
Pfizer CEO Albert Bourla is breathing a little easier after strong third quarter earnings results Tuesday and after the company raised full-year guidance by $1.5 billion, bringing an end to a ...
Image source: The Motley Fool. Pfizer (NYSE: PFE) Q3 2024 Earnings Call Oct 29, 2024, 10:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call ...
Excluding one-time items, Pfizer reported a loss of 17 cents per share compared with analysts' expectations for a loss of 34 cents, and a profit of $1.78 per share a year ago.
Pfizer (PFE) suffers massively in 2019 due to aggressive business development activity, incremental currency woes and loss of exclusivity of key drug Lyrica. But it is poised to have a better 2020.
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, the 10-Q is an SEC filing that must be filed quarterly with the US Securities and Exchange Commission. It contains similar information to the annual form 10-K , however the information is generally less detailed, and the financial statements are generally unaudited .
Pfizer's (PFE) fourth-quarter earnings and sales beat estimates. Its forecast for 2019 falls short of expectations. Stock dips 2% in pre-market trading.
Margins matter. The more Pfizer (NYS: PFE) keeps of each buck it earns in revenue, the more money it has to invest in growth, fund new strategic plans, or (gasp!) distribute to shareholders.
Pfizer (PFE) performs better than the industry in 2018 and looks well poised to keep the positive momentum alive in 2019.